AZD9291と新規治療薬の漸増投与との併用

基本情報

NCT ID: NCT02143466
ステータス: 実施中（募集終了）
試験のフェーズ: 第1相
試験タイプ: 介入
目標被験者数: 344
治験依頼者名: AstraZeneca

概要

The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer

対象疾患

Advanced Non Small Cell Lung Cancer

介入

Part A - AZD9291 in combination with AZD6094(DRUG)

Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)(DRUG)

Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)(DRUG)

Part A - AZD9291 in combination with intermittent selumetinib(DRUG)

Part A - AZD9291 in combination with MEDI4736(DRUG)

Part B - AZD9291 in combination with AZD6094(DRUG)

Part B - AZD9291 in combination with selumetinib(DRUG)

Part B - AZD9291 in combination with MEDI4736(DRUG)

Part C - AZD6094 monotherapy (Japan only)(DRUG)

Part C - AZD9291 in combination with AZD6094 (Japan only)(DRUG)

Part D - AZD9291 in combination with AZD6094(DRUG)

依頼者（Sponsor）

アストラゼネカ株式会社(INDUSTRY)